User:Tkadm30/Notebook/Endocannabinoids/Anandamide: Difference between revisions
From OpenWetWare
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* Anandamide appears a good target to activate TRPV1 receptor and trigger antiepileptogenesis. | * Anandamide appears a good target to activate TRPV1 receptor and trigger antiepileptogenesis. | ||
* Anandamide provides on demand neuroprotection agaisnt in vivo excitotoxicity and neuroinflammation. [https://www.ncbi.nlm.nih.gov/pubmed/12764100 PMID] | * Anandamide provides on demand neuroprotection agaisnt in vivo excitotoxicity and neuroinflammation. [https://www.ncbi.nlm.nih.gov/pubmed/12764100 PMID] | ||
=== See also === | |||
* [[User:Etienne_Robillard/Notebook/TRPV1|TRPV1 Notebook]] | |||
Revision as of 06:26, 14 August 2015
Anandamide (N-arachidonoyl-ethanolamine)
- Biosynthesis of endogenous phosphoanandamide/PLC ligands: PMID
- Cannabinoid receptor type 1 (CB1) partial agonist PMID
- Anandamide signaling is metabotropic (CB1) and limit TRPV1-mediated Ca2+ influx. PMID
- Anandamide appears a good target to activate TRPV1 receptor and trigger antiepileptogenesis.
- Anandamide provides on demand neuroprotection agaisnt in vivo excitotoxicity and neuroinflammation. PMID
